help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 Click here to read this article as a CME course

First Published Online September 29, 2009
The Oncologist, Vol. 14, No. 10, 1021-1038, October 2009; doi:10.1634/theoncologist.2009-0194
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2009-0194v1
14/10/1021    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Landa, J.
Right arrow Articles by Schwartz, L. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Landa, J.
Right arrow Articles by Schwartz, L. H.

Sarcomas

Contemporary Imaging in Sarcoma

Jonathan Landa, Lawrence H. Schwartz

Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Key Words. Sarcoma • Functional imaging • Positron emission tomography (PET) • Magnetic resonance imaging

Correspondence: Jonathan Landa, D.O., Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-3774; Fax: 212-717-3234; e-mail: landaj{at}mskcc.org

Received August 20, 2009; accepted for publication August 31, 2009; first published online in THE ONCOLOGIST Express on September 29, 2009.

Disclosures

Jonathan Landa: None; Lawrence H. Schwartz: Consultant/advisory role: Cancer and Leukemia Group B (CALGB), Sarcoma Alliance for Research through Collaboration (SARC); Research funding/contracted research: AstraZeneca.

Section editor Jaap Verweij has disclosed no financial relationships relevant to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Sarcomas are a heterogeneous group of >50 subtypes of neoplasm. It is imperative to obtain appropriate imaging of these tumors in order to adequately assess, characterize, and stage bone and soft tissue sarcomas. Anatomic imaging such as radiographs, computed tomography, and magnetic resonance imaging (MRI) remain the foundation for both biopsy planning and postoperative evaluation of these neoplasms. However, anatomic imaging may not be entirely accurate in the evaluation of treatment response. Newer techniques, such 18F-fluorodeoxyglucose positron emission tomography, are being used to evaluate distant metastases. Newer radiopharmaceuticals, such as 18F-fluorodeoxythymidine, are being developed to assist in the differentiation between benign and low-grade malignant neoplasms. Newer functional imaging techniques, such as dynamic contrast-enhanced MRI and diffusion-weighted imaging, among others, are being developed to evaluate treatment response.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.